Skip to content
2000
image of A Descriptive Analysis from VigiAccess on Drug-related ProblemsAssociated with the Glucagon-like Peptide-1 Receptor Agonists

Abstract

Introduction

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely accepted for managing Type 2 Diabetes Mellitus. However, numerous drug-related problems (DRPs) have recently been reported about GLP-1 RAs. The present descriptive study aims to compile and report the DRPs of various GLP-1 RAs.

Methods

The DRPs reported for all the GLP-1 RAs, including exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and trazeptide, were extracted from the category of injury, poisoning, and procedural complications of VigiAccess. The Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1) was used to categorize the DRPs into patient-related, healthcare practice-related, and patient- or healthcare practice-related.

Results

Overall, 315952 potential side effects (PSEs) were reported regarding GLP-1 RAs in VigiAccess under injury, poisoning, and procedural complications. Out of 315952 PSE reports, 84187 were DRPs of GLP-1 RAs. Among the patient-related DRPs, the administered incorrect dose (17797; 48.37%) was predominant, and most of the reports were documented for tirzepatide (9993; 23.82%). Off-label use (13600; 48.37%) was a predominant healthcare practice-related DRP, most of which were from Tirzepatide (4945; 17.59%).

Discussion

The alarming DRP reports in this descriptive analysis regarding the dosing and off-label use of GLP-1 Ras need further investigation to establish the contribution of underlying factors.

Conclusion

Qualified healthcare practitioners must educate the patients administering the GLP-1 RAs to minimize preventable DRPs. Also, careful and frequent monitoring of GLP-1 RAs improves therapeutic outcomes by ruling out DRPs. Healthcare practitioners should comply with approved therapeutic guidelines to enhance the treatment quality of GLP-1 RAs.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863367086250420011411
2025-05-07
2025-09-16

  • From This Site

    /content/journals/cds/10.2174/0115748863367086250420011411
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Goyal R. Singhal M. Jialal I. Type 2 Diabetes. StatPearls. Treasure Island, FL StatPearls Publishing 2024 https://www.ncbi.nlm.nih.gov/books/NBK513253/
    [Google Scholar]
  2. Atlas I.D.F. Available from: International Diabetic Federation. https://diabetesatlas.org/atlas/tenth-edition/
  3. American Diabetes Association. Oral and injectable medications for type-2 diabetes mellitus. 2024 Available from: https://diabetes.org/health-wellness/medication/oral-other-injectable-diabetes-medications
  4. King A. Miller E.M. Glucagon-like peptide 1 receptor agonists have the potential to revolutionize the attainment of target A1C levels in type 2 diabetes—So why is their uptake so low? Clin. Diabetes 2023 41 2 226 238 10.2337/cd22‑0027 37092151
    [Google Scholar]
  5. Drucker D.J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 2024 47 11 1873 1888 10.2337/dci24‑0003 38843460
    [Google Scholar]
  6. ElSayed N.A. Aleppo G. Bannuru R.R. Bruemmer D. Collins B.S. Ekhlaspour L. Gaglia J.L. Hilliard M.E. Johnson E.L. Khunti K. Lingvay I. Matfin G. McCoy R.G. Perry M.L. Pilla S.J. Polsky S. Prahalad P. Pratley R.E. Segal A.R. Seley J.J. Stanton R.C. Gabbay R.A. American Diabetes Association Professional Practice Committee Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2024. Diabetes Care 2024 47 Suppl. 1 S158 S178 10.2337/dc24‑S009 38078590
    [Google Scholar]
  7. Holst J.J. Ørskov C. Vagn Nielsen O. Schwartz T.W. Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut. FEBS Lett. 1987 211 2 169 174 10.1016/0014‑5793(87)81430‑8 3542566
    [Google Scholar]
  8. Mojsov S. Weir G.C. Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987 79 2 616 619 10.1172/JCI112855 3543057
    [Google Scholar]
  9. Collins L. Costello R.A. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Internet Treasure Island, FL StatPearls Publishing 2024 https://www.ncbi.nlm.nih.gov/books/NBK551568/
    [Google Scholar]
  10. Back H.M. Choi S.A. Kim M.G. Adverse events of GLP-1 receptor agonists for weight loss: Twitter and a national pharmacovigilance database. Drug Targets. Therap. 2023 2 1 41 48 10.58502/DTT.23.0003
    [Google Scholar]
  11. Sodhi M. Rezaeianzadeh R. Kezouh A. Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 2023 330 18 1795 1797 10.1001/jama.2023.19574 37796527
    [Google Scholar]
  12. Shetty R. Basheer F.T. Poojari P.G. Thunga G. Chandran V.P. Acharya L.D. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab. Syndr. 2022 16 3 102427 10.1016/j.dsx.2022.102427 35217468
    [Google Scholar]
  13. Wan J. Ferrari C. Tadros M. GLP-1RA essentials in gastroenterology: Side Effect Management, precautions for endoscopy and applications for gastrointestinal disease treatment. Gastroenterol. Insights 2024 15 1 191 212 10.3390/gastroent15010014
    [Google Scholar]
  14. Filippatos T.D. Panagiotopoulou T.V. Elisaf M.S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 2014 11 3-4 202 230 10.1900/RDS.2014.11.202 26177483
    [Google Scholar]
  15. Hidayat K. Zhou Y.Y. Du H.Z. Qin L.Q. Shi B.M. Li Z.N. A systematic review and meta‐analysis of observational studies of the association between the use of incretin‐based therapies and the risk of pancreatic cancer. Pharmacoepidemiol. Drug Saf. 2023 32 2 107 125 10.1002/pds.5550 36224724
    [Google Scholar]
  16. 16. FDA alerts healthcare providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products. Available from: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  17. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA’s concerns with unapproved GLP-1 drugs used for weight loss. 2024 Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  18. Europe PC PCNE classification for drug-related problems. 9.1 1 2010 Available from: https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf
    [Google Scholar]
  19. World Health Organization VigiAccess- The WHO global database of reported potential side effects of medicinal products. 2024 Available from: https://www.vigiaccess.org/
  20. Yamoah P. Mensah K.B. Attakorah J. Padayachee N. Oosthuizen F. Bangalee V. Adverse events following immunization associated with coronavirus disease 2019 (COVID-19) vaccines: A descriptive analysis from VigiAccess. Hum. Vaccin. Immunother. 2022 18 6 2109365 10.1080/21645515.2022.2109365 35947052
    [Google Scholar]
  21. Liang Q Liao X Wu H Huang Y Liang T Li H Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases. Front Pharmacol. 2024 15 1431562 10.3389/fphar.2024.1431562
    [Google Scholar]
  22. Kim M. Investigating the status of WHO vigiaccess adverse drug event reporting and exploring its potential for application using anti-obesity agents as examples. J. Int. Korean. Med. 2024 45 1 55 74 10.22246/jikm.2024.45.1.55
    [Google Scholar]
  23. Li M You R Su Y Zhou H Gong S Characteristic analysis of adverse reactions of five anti-TNFɑ agents: A descriptive analysis from WHO-VigiAccess. Front Pharmacol. 2023 14 1169327 10.3389/fphar.2023.1169327
    [Google Scholar]
  24. Pharmaceutical Care Network Europe Association (PCNE) classification for drug-related problems (version 9.1). 2024 Available from: https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf
  25. Thieu V.T. Robinson S. Kennedy-Martin T. Boye K.S. Garcia-Perez L.E. Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes. Patient Prefer. Adherence 2019 13 561 576 10.2147/PPA.S187907 31114170
    [Google Scholar]
  26. Brooks A. Langer J. Tervonen T. Hemmingsen M.P. Eguchi K. Bacci E.D. Patient preferences for GLP-1 receptor agonist treatment of type 2 Diabetes Mellitus in Japan: A discrete choice experiment. Diabetes Ther. 2019 10 2 735 749 10.1007/s13300‑019‑0591‑9 30847838
    [Google Scholar]
  27. Wettergreen S.A. Stewart M.P. Kennedy K. Trujillo J.M. Comparison of the usability, accuracy, preference, and satisfaction of three once-weekly glucagon-like peptide 1 receptor agonist pen devices in people with type 2 diabetes. Diabetes Spectr. 2023 36 1 5 13 10.2337/ds21‑0108 36818408
    [Google Scholar]
  28. Reid T.S. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin. Diabetes 2013 31 4 148 157 10.2337/diaclin.31.4.148
    [Google Scholar]
  29. Kalra B. Kalra S. Counselling patients for GLP-1 analogue therapy: Comparing GLP-1 analogue with insulin counselling. N. Am. J. Med. Sci. 2012 4 12 638 640 10.4103/1947‑2714.104315 23272306
    [Google Scholar]
  30. Ashraf AR Mackey TK Schmidt J Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open 2024 7 8 e2428280 10.1001/jamanetworkopen.2024.28280
    [Google Scholar]
  31. Han S.H. Ockerman K. Furnas H. Mars P. Klenke A. Ching J. Momeni A. Sorice-Virk S. Practice patterns and perspectives of the off-label use of GLP-1 agonists for cosmetic weight loss. Aesthet. Surg. J. 2024 44 4 NP279 NP306 10.1093/asj/sjad364 38085071
    [Google Scholar]
  32. Mary PG Marina B Emma LO Nicole R Emily B Margaret Z Donna E Jason NG Carol J L Osagie E Understanding off-label use of GLP-1 (Glucagon-Like Peptide-1 Receptor) agonists among providers participating in the T1D exchange quality improvement collaborative (T1DX-QI). Diabetes 2024 73 1 804 10.2337/db24‑804‑P
    [Google Scholar]
  33. Hershkowitz I. Cahn A. Prescription patterns in people who are frail. Lancet Healthy Longev. 2023 4 10 e522 e523 10.1016/S2666‑7568(23)00177‑0 37734396
    [Google Scholar]
  34. Wei ET Koh E Kelly MS Wright LA Tylee TS Patient errors in use of injectable antidiabetic medications: A need for improved clinic-based education. J. Am. Pharm. Assoc 2020 60 5 e76 10.1016/j.japh.2020.02.030
    [Google Scholar]
  35. Blum D. The Wegovy shortage continues, leaving patients on the weight loss drug in limbo. 2023 Available from: https://www.nytimes.com/2023/10/05/well/live/wegovy-shortageozempic-fda.html
    [Google Scholar]
  36. Baig K. Dusetzina S.B. Kim D.D. Leech A.A. Medicare Part D coverage of antiobesity medications—challenges and uncertainty ahead. N. Engl. J. Med. 2023 388 11 961 963 10.1056/NEJMp2300516 36912541
    [Google Scholar]
  37. Liu B.Y. Rome B.N. State coverage and reimbursement of antiobesity medications in Medicaid. JAMA 2024 331 14 1230 1232 10.1001/jama.2024.3073 38483403
    [Google Scholar]
  38. Lorenzi G. Schreiner B. Osther J. Boardman M. Application of adult-learning principles to patient instructions: A usability study for an exenatide once-weekly injection device. Clin. Diabetes 2010 28 4 157 162 10.2337/diaclin.28.4.157
    [Google Scholar]
  39. Zhou A.Y. Trujillo J.M. Comparison of usability, accuracy, preference, and satisfaction among three once-weekly GLP-1 receptor agonist pen devices. Diabetes Spectr. 2018 31 4 359 366 10.2337/ds17‑0048 30510393
    [Google Scholar]
  40. Moore H.E. Zaya V. Burns C.V. Berlie H.D. Accidental once-daily use of Dulaglutide: A case report. Clin. Diabetes 2024 42 3 454 457 10.2337/cd23‑0035 39015162
    [Google Scholar]
  41. Bridges A. Bistas K.G. Jacobs T.F. Exenatide. StatPearls. Treasure Island, FL StatPearls Publishing 2024
    [Google Scholar]
  42. Mother To Baby | Fact Sheets. Brentwood Organization of Teratology Information Specialists (OTIS) 1994 https://www.ncbi.nlm.nih.gov/books/NBK605070/
    [Google Scholar]
  43. Mother To Baby | Fact Sheets. Semaglutide Organization of Teratology Information Specialists (OTIS) 1999
    [Google Scholar]
  44. Muller DRP Stenvers DJ Malekzadeh A Holleman F Painter RC Siegelaar SE Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: A systematic review of the evidence. Front Endocrinol (Lausanne). 2023 14 1215356 10.3389/fendo.2023.1215356
    [Google Scholar]
  45. Lynch M.M. Amoozegar J.B. McClure E.M. Squiers L.B. Broussard C.S. Lind J.N. Polen K.N. Frey M.T. Gilboa S.M. Biermann J. Improving safe use of medications during pregnancy: The roles of patients, physicians, and pharmacists. Qual. Health Res. 2017 27 13 2071 2080 10.1177/1049732317732027 28974142
    [Google Scholar]
  46. Berman C. Vidmar A.P. Chao L.C. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes in youth. Eur. Endocrinol. 2023 19 1 38 45 10.17925/EE.2023.19.1.38 37313232
    [Google Scholar]
  47. Aldhaleei WA Abegaz TM Bhagavathula AS Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: A cross-sectional analysis of the national institutes of health all of us cohort. Pharmaceuticals 2024 17 2 199 10.3390/ph17020199
    [Google Scholar]
  48. Tan Q Akindehin SE Orsso CE Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol (Lausanne). 2022 13 838410 10.3389/fendo.2022.838410
    [Google Scholar]
/content/journals/cds/10.2174/0115748863367086250420011411
Loading
A Descriptive Analysis from VigiAccess on Drug-related ProblemsAssociated with the Glucagon-like Peptide-1 Receptor Agonists
Bentham Science Publishers ; https://doi.org/10.2174/0115748863367086250420011411
/content/journals/cds/10.2174/0115748863367086250420011411
/content/journals/cds/10.2174/0115748863367086250420011411
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: off-label use ; glucagon-like peptide-1 receptor agonists ; type-2 diabetes mellitus ; Drug-related problems ; VigiAccess ; potential side effects

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test